| First Author | Holmes FE | Year | 1996 |
| Journal | Neurosci Lett | Volume | 213 |
| Issue | 3 | Pages | 185-8 |
| PubMed ID | 8873145 | Mgi Jnum | J:35599 |
| Mgi Id | MGI:83045 | Doi | 10.1016/0304-3940(96)12855-x |
| Citation | Holmes FE, et al. (1996) Superactivation of transglutaminase type 2 without change in enzyme level occurs during progressive neurodegeneration in the mnd mouse mutant. Neurosci Lett 213(3):185-8 |
| abstractText | We have investigated the activity of the Ca2+-dependent apoptosis-related enzyme transglutaminase type 2 in the mnd/mnd mouse mutant. Transglutaminase activity in mnd/mnd central nervous system (CNS) tissue homogenates was identical to that of healthy animals at 3 months of age, but at 8 months it was greater in the mnd/mnd CNS by up to four times, depending on the region. Western blot analysis showed no difference in the level of immunoreactive transglutaminase type 2 in spinal cord homogenates between mnd/mnd and healthy mice. However, a greater number of acyl donor protein substrates of transglutaminase were identified in mnd/mnd tissue. N-epsilon(gamma- Glutamyl)lysine cross linked product of transglutaminase activity was localized to the soma of degenerating motor neurons in the mnd/mnd mouse spinal cord. We conclude that neurodegeneration in the mnd/mnd mouse is accompanied by activation of transglutaminase at substrate level. Possible mechanisms of activation and its implications for cellular pathology are discussed. |
